Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings
I'm LongbridgeAI, I can summarize articles.
Shares of Daiichi Sankyo fell nearly 11% to 2,497.50 yen after the company delayed its earnings report for the fiscal year ending March 2026 to May 11, citing a review of its oncology portfolio and contract manufacturing provisions. The company also plans to release its five-year business plan for 2026-2030 on the same date. This delay occurs as Daiichi Sankyo shifts towards innovative drug discovery, having recently sold its over-the-counter drug business to Suntory Holdings for $1.55 billion. The stock is down nearly 26% this year.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments